Adverum Biotechnologies, Inc. (ADVM)

Market Cap	96.26M -19.5%
Revenue (ttm)	n/a -72.2%
Net Income	-184.79M
EPS	-8.56
Shares Out	22.08M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,023,039
Open	4.240
Previous Close	4.260
Day's Range	4.230 - 4.379
52-Week Range	1.780 - 6.120
Beta	0.87
Analysts	Buy
Price Target	11.60 (+166.06%)
Earnings Date	Nov 12, 2025

About ADVM

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec Ixo-vec, a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing BGTF-027 (AAV.7m8-L-opsin), a novel gene therapy product candidate designed to deliver a functional copy of the OPN1LW gene to the foveal co...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 31, 2014
• Employees: 155
• Stock Exchange: NASDAQ
• Ticker Symbol: ADVM
• Website: https://adverum.com

Financial Performance

In 2024, Adverum Biotechnologies's revenue was $1.00 million, a decrease of -72.22% compared to the previous year's $3.60 million. Losses were -$130.93 million, 7.22% more than in 2023.

Analyst Summary

According to 5 analysts, the average rating for ADVM stock is "Buy." The 12-month stock price target is $11.6, which is an increase of 166.06% from the latest price.

Price Target

$11.6

(166.06% upside)

Analyst Consensus: Buy